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Abstract: The reproductive biology of the domestic dog is unique among mammalian species; because of this, in vitro maturation (IVM)
rate is still very low compared with other domestic animals in spite of attempts at improvement. The aim of this study was to consider the
use of recombinant human gonadotropins as a replacement for pituitary gonadotropins for IVM of dog oocytes. A total of 845 cumulus–
oocyte complexes were used in this study. To determine the effects of human recombinant gonadotropins, maturation medium was
supplemented with two different concentrations (0.05 or 0.1 IU/mL) of pituitary (pFSH, pLH) and human recombinant (rhFSH and
rhLH) gonadotropins. After the IVM period, the maturation rate of the oocytes was investigated under an epifluorescence microscope.
Our findings showed no significant difference in maturation rate using either pituitary or human recombinant gonadotropin groups
(P > 0.05). Applying 1.0 IU human recombinant gonadotropin caused the lowest maturation rate (34.57%; P < 0.05). In conclusion,
recombinant human gonadotropins could be applied for IVM of dog oocytes. Moreover, 0.05 IU/mL rhFSH and rhLH can be successfully
used in place of biologically derived hormones.
Key words: Dog oocyte, in vitro maturation, recombinant gonadotropin hormone

1. Introduction
Dogs and humans are quite similar in physiology,
anatomical structure, and responses to drugs and irradiation
(1). Moreover, about half of the genetic diseases found in
humans are also reported in dogs, which makes them a
better model than mice for human hereditary diseases (2).
It is known that assisted reproduction techniques such
as in vitro maturation (IVM), in vitro fertilization (IVF),
and somatic cell nuclear transfer (SCNT) may contribute
considerably to protection of endangered species (3,4).
In vivo follicle development is arranged by folliclestimulating hormone (FSH), luteinizing hormone (LH),
and inhibin, with coordination of the gonadal–pituitary
axis (5). Reproductive physiology of the domestic dog
is different from that of most other species; ovulation
occurs when the oocyte is immature, and maturation is
completed in the oviduct within 48–72 h (6). The proteins
produced by LH are responsible for the expansion of the
cumulus cells. Expansion of these cells is considered a
cytoplasmic maturation indicator in mammals and used
for determination of oocyte maturation rates during
in vitro fertilization studies. However, cumulus cell

expansion is rare and appears to be insignificant for IVM
of dog oocytes (7). It is difficult to identify the stimulant
or repressive components; the meiotic results of in vitro
matured dog oocytes are still unobservable. Furthermore,
the success of in vitro technologies is still very limited in
dogs (4,8). Previously, our attempts to mimic the in vivo
hormone secretion mechanism of dogs showed an in vitro
maturation rate lower than 50% (9). The low IVM rates in
dogs are the main cause of IVF and subsequent embryonic
development failures (4). To our knowledge, only one
blastocyst (10) and two morula-stage embryos (10,11)
have been achieved using in vitro fertilization of immature
dog oocytes. Despite live pups being born from SCNT
of dog oocytes, success of in vivo maturation (12), and
detection of one pregnancy (13), no offspring have been
reported by transferring embryos produced from in vitro
matured canid oocytes. Moreover, results of studies using
in vivo matured dog oocytes have also been disappointing.
Only seven (14) and six (15) healthy puppies were
delivered in the two most successful trials until date.
Reliable systems for in vitro embryo production have not
yet been developed, and new approaches are needed for
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dogs (9,11). The cost of pituitary gonadotropins (FSH and
LH) is considered an obstacle for in vitro studies in dogs,
with low success rates as well. Therefore, the availability
of a less costly hormone source may allow for further
research. Recombinant human gonadotropins (rhFSH
and rhLH) are considered much cheaper than pituitary
hormones (pFSH and pLH). These hormones have been
used previously for in vitro studies of sheep (16–18), cats
(19), humans, cattle, and mice (20,21), and have produced
successful results for IVM of oocytes and development
rate of embryos. This study was conducted to investigate
for the first time the in vitro maturation of dog oocytes
using recombinant human gonadotropins.
2. Materials and methods
Ethical approval for animal studies was granted by
the İstanbul University Ethics Committee on Animal
Research (2018/111555). Unless otherwise mentioned, all
chemicals were purchased from Sigma Aldrich (St. Louis,
MO, USA).
2.1. Collection of oocytes
Ovaries were obtained from 20 spayed bitches in the
anestrous cycle stage after routine ovariohysterectomy
at the Avcılar Municipality Stray Animals Sterilization
and Rehabilitation Center. Ovaries were maintained and
transported to the laboratory in cold physiological saline
at 4 °C until oocyte recovery within 2–3 h. Ovaries were
left at room temperature for 20 min for rewarming. After
slicing, ovaries were washed using HEPES modified
TCM 199 washing medium to gather cumulus–oocyte
complexes (COCs). Afterwards, COCs were washed
using modified synthetic oviduct fluid medium (mSOF)
and selected based on a number of criteria, namely being
surrounded by at least four cumulus cell layers, and having
a dark-pigmented ooplasm and an intact zona pellucida.
2.2. In vitro maturation
In vitro maturation was performed as elucidated in our
previous study with minor modifications (9). In brief, the
maturation procedure was performed in mSOF medium
(270 mOsm, pH 7.2) supplemented with 4% BSA (fraction
V), MEM amino acids solution, nonessential amino acids
solution, antibiotics, and epidermal growth factor (EGF;
20 ng/mL). The selected COCs were transferred into
petri dishes including 50 µL of maturation medium drops
covered with mineral oil. Petri dishes were maintained
at 38 °C in a humidified atmosphere with 5% CO2 for 72
h. Depending on the experiment, maturation medium
was supplemented with two different concentrations of
pituitary FSH (pFSH), LH (pLH), and human recombinant
FSH (rhFSH, Gonal-F, Merck, İstanbul, Turkey) and LH
(rhLH, Luveris, Merck, İstanbul, Turkey).
To determine the in vitro effect of rhFSH and rhLH
on maturation rates of oocytes and to compare them
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with pituitary gonadotropins (pFSH and pLH), the study
groups were designed as follows:
1. Group: Control (no gonadotropin);
2. Group: 0.5 IU pituitary group (0.05 IU/mL pFSH +
0.05 IU/mL pLH);
3. Group: 1.0 IU pituitary group (0.1 IU/mL pFSH +
0.1 IU/mL pLH);
4. Group: 0.5 IU human recombinant group (0.05 IU/
mL rhFSH + 0.05 IU/mL rhLH);
5. Group: 1.0 IU human recombinant group (0.1 IU/
mL rhFSH + 0.1 IU/mL rhLH).
2.3. Evaluation of nuclear maturation rates
To remove the cumulus cells after the determined in
vitro maturation period, oocytes were placed into hSOF
medium containing 0.4% (w/v) hyaluronidase and
then vortexed for 2 min. Swelling the chromatins was
performed by transferring the oocytes to hypotonic KCl
solution (0.7%, w/v) for 5 min. The oocyte maturation
rates were examined using an epifluorescence microscope
after staining with Hoechst 33342 for 20–30 min.
3. Results
3.1. In vitro maturation rate
Maturation rates of dog oocytes are presented in the Table.
The highest IVM (metaphase I + metaphase II) rates were
found in the 0.5 and 1.0 IU pituitary gonadotropin groups,
and these rates were statistically similar (52.41% and
49.73%, respectively; P > 0.05). The 0.5 IU recombinant
hormone group resulted in a rate of 43.64% without
a statistical difference from the 1.0 IU pituitary group
(49.73%). However, IVM was lower than in the 0.5 IU
treated group. The lowest maturation rate was observed
in the 1.0 IU recombinant gonadotropin group (34.57%;
P < 0.05). Despite the lack of statistical significance, an
appreciable decrease in rate of maturation using 0.5 IU
recombinant hormone was detected compared with
the control group (38.18%). The highest rate of oocytes
remaining in the germinal vesicle (GV) stage was found
in the 1.0 IU recombinant gonadotropin group (20.99%;
P < 0.05). However, there were no statistically significant
differences between all groups according to germinal
vesicle breakdown (GVBD) and undetermined nuclear
material (UDNM) parameters (Figures 1A–1F).
3.2. Statistical analysis
The statistical analysis of the study was carried out using
Pearson’s chi-square test by SPSS 13.0 for Windows (SPSS
Corp., Chicago, IL, USA).
4. Discussion
Mammalian oocytes get their meiotic signals via gap
junction communication with cumulus cells (22).
Gonadotropins are regulated with cyclic adenosine
3’,5’-monophosphate (cAMP) and subsequent activation of
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Table. Meiotic competence of dog oocytes after in vitro oocyte maturation for 72 h in the presence of different
concentrations (0.05–0.1 IU/mL) of pituitary (p) and recombinant human (rh) gonadotropins.
Developmental stages and rates % (cell numbers)
Groups

n
GV

GVBD

MI

MII

MI + MII

UDNM

Control
(No gonadotropins)

165

10.30 b
(17/165)

30.30
(50/165)

33.94 b
(56/165)

4.24
(7/165)

38.18 b
(63/165)

21.21
(35/165)

0.05 IU/mL
pFSH + pLH

166

16.87 ab
(28/166)

19.28
(32/166)

46.39 a
(77/166)

6.02
(10/166)

52.41 a
(87/166)

11.45
(19/166)

0.1 IU/mL
pFSH + pLH

187

11.77 b
(22/187)

25.67
(48/187)

48.13 a
(90/187)

1.60
(3/187)

49.73 a
(93/187)

12.83
(24/187)

0.05 IU/mL
rhFSH + rhLH

165

12.73 b
(21/165)

28.49
(47/165)

39.40 ab
(65/165)

4.24
(7/165)

43.64 ab
(72/165)

15.15
(25/165)

0.1 IU/mL
rhFSH + rhLH

162

20.99 a
(34/162)

29.63
(48/162)

29.63 b
(48/162)

4.94
(8/162)

34.57 b
(56/162)

14.82
(24/162)

Values with different superscripts in the same column are significantly different (P < 0.05).
pFSH: Pituitary follicle stimulating hormone; pLH: pituitary luteinizing hormone.
rhFSH: Recombinant human follicle stimulating hormone; rhLH: recombinant human luteinizing hormone.
GV: Germinal vesicle; GVBD: germinal vesicle breakdown; MI: metaphase I; MII: metaphase II; UDNM:
undetermined nuclear material.
a, b, c

Figure 1. Canine oocytes stained with Hoechst 33342 and visualized under an epifluorescence microscope. A) Germinal vesicle; B)
germinal vesicle breakdown; C) degenerated; D) metaphase I; E) metaphase II; F) undetermined nuclear material (UDNM) (200×
magnification).
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mitogen-activated protein kinase (MAPK) (23). Although
the meiotic resumption is stimulated by gonadotropins
in mammals, its mechanism is still not fully understood.
It has been demonstrated that human recombinant
gonadotropins stimulate ovulation, maturation, and
steroidogenesis in rats (24). Moreover, rhFSH alone or
combined with rhLH in the presence of estrogens could
have inducement efficacy on progression of the meiotic
cycle of sheep oocytes (18). Ability of rhFSH and rhLH
to cause complete in vitro maturation and embryonic
development has been demonstrated for the first time
in bovine oocytes (20). However, previous studies
reported similar results for recombinant gonadotropins
on human embryonic development (25). It was stated
that rhFSH at doses of 0.1–1.0 IU/mL was appropriate
to stimulate in vitro oocyte maturation and subsequent
embryo development in domestic cat (19). In contrast,
the present study indicates that the highest maturation
rates were induced using pituitary gonadotropin (pFSH
+ pLH), while the lowest maturation rates were found in
the control and 1.0 IU recombinant human gonadotropin
groups (38% and 34%, respectively). Furthermore, our
findings were in contrast with other studies that stated
that gonadotropins are not required for in vitro meiosis
in cultured mammalian oocytes (26). The presented data
showed that the physiological processes and in vitro
environmental requirement of dog oocytes differ from
other mammalian oocytes.
Contamination of biologically derived hormones
with minor components may play an important role
on in vitro oocyte quality and viability (20). Previously,
we found that applying recombinant gonadotropin in
cats at 0.5 IU/mL was superior to pituitary hormones
in inducing maturation (44.62%) (27). In this study the

1.0 IU human recombinant gonadotropin group had
dramatically decreased maturation rates of dog oocytes.
Although the 0.5 IU human recombinant gonadotropin
results (43.64%) were statistically similar to 0.5 IU and 1.0
IU pituitary results (52.41% and 49.73%), the results from
1.0 IU recombinant gonadotropins (34.57%) were lower
than even those of the control group (38.14%). These
findings indicated that dog and cat oocytes might require
other factors, such as pituitary-based thyroid stimulating
hormone (TSH) or other biological components, during
the long-term maturation process. It is known that FSH
has a positive effect on the expansion of cumulus cells as
well as a positive correlation with the meiotic development
ability in mammalian oocytes (28). In contrast to this
knowledge, it is declared that the IVM rate of canine
oocytes is negatively correlated with cumulus expansion
rates. Moreover, the presence of gonadotropins for
the culture period has a negative effect on the nuclear
maturation rates (29). Although bovine somatotropin
increased the rate of blue fox oocytes reaching the MII
stage, no effect on nuclear maturation was observed in
dogs (30). These findings demonstrate that there is some
divergence between canines and other mammals and even
among canid species in the response of their oocytes to
hormone supplementation. It has been concluded that 0.5
IU recombinant human gonadotropin could give results
similar to those of biologically derived hormones and thus
can be used instead of biologically derived hormones for
in vitro oocyte maturation in dogs.
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